Oesophageal cancer, oesofaguscarcinoom, esophageal cancer, active surveillance
Conditions
Interventions
Approximately 4-6 weeks after completion of nCRT all patients will undergo a first clinical response evaluation (CRE-I) consisting of endoscopy with (random) bite-on-bite biopsies of the primary tumou
Sponsors
Erasmus MC
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Patients who are planned to undergo neoadjuvant chemoradiotherapy according to CROSS, followed by surgical resection for histologically proven oesophageal squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophago-gastric junction, without distant dissemination; - Age =18; - Written, voluntary, informed consent.
Exclusion criteria
Exclusion criteria: - Language difficulty, dementia or altered mental status prohibiting the understanding and giving of informed consent and to complete quality of life questionnaires; - Non-FDG-avid tumour at baseline PET-CT scan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Overal survivall | — |
Secondary
| Measure | Time frame |
|---|---|
| - Percentage of patients in active surveillance arm who do not undergo surgery (i.e. patients who are cured by neoadjuvant chemoradiotherapy or who have occult distant metastases during initial staging. | — |
Contacts
Public ContactBerend Wilk, van der
Afdeling Heelkunde, Erasmus MC, Kamer Z-836
Outcome results
None listed